A case study of atypical hemolytic uremic syndrome (aHUS) caused by a new mutation in the DGKE gene highlights the disease’s early onset and severe difficult-to-treat course. The report, “Clinical features and management of atypical hemolytic uremic syndrome patient with DGKE gene variants: a case report,”…
News
A young adult with atypical hemolytic uremic syndrome (aHUS) in India successfully received a transplanted kidney from a donor with an incompatible blood type, a recent case study says. The report — the first to document such a case in someone diagnosed with aHUS — demonstrates that blood-type-incompatible…
Soliris (eculizumab) was effective in enhancing kidney disease-free survival in patients with atypical hemolytic uremic syndrome (aHUS), a real-world study reported. Specifically, data showed Soliris was able to increase patients’ five-year survival rate without signs of kidney disease by nearly five times. According to authors, this was the…
Areas of brain damage caused by a lack of blood supply were found in a patient with atypical hemolytic uremic syndrome (aHUS), a case study reports. Treatment with Soliris (eculizumab) ultimately resolved the patient’s neurological symptoms. According to the authors, the case shows this type of brain damage…
A boy with atypical hemolytic uremic syndrome (aHUS) experienced a disease relapse followed by unusual symptoms, including bone tissue death and gallstones, after pausing treatment with Soliris (eculizumab). His case was described in the report, “Bilateral hip osteonecrosis and cholelithiasis after eculizumab discontinuation in atypical…
People with atypical hemolytic uremic syndrome (aHUS) have an immune cell profile distinct from that of healthy people and unaffected family members, a recent study reported. Its scientists identified a range of immune cell types, genes, and signaling pathways that could ultimately serve as disease biomarkers — with the…
Short-term use of Soliris (eculizumab) successfully treated atypical hemolytic uremic syndrome (aHUS) that had no genetic link in two young adults, one with a rare infection and the other with a rare autoimmune condition, according to a case report. Both men lacked variants in complement genes that can…
People with atypical hemolytic uremic syndrome (aHUS) who start treatment with Soliris (eculizumab) or Ultomiris (ravulizumab) — both marketed by Alexion — generally use fewer healthcare resources, according to a new U.S. study. Indeed, rates of insurance claims for aHUS patients starting on either therapy dropped substantially…
Reduced capillary density and capillary abnormalities were identified in people with atypical hemolytic uremic syndrome (aHUS) using a nailfold dermoscopy, a study in Turkey reports. Nailfold dermoscopy is a noninvasive technique that lets doctors evaluate the small blood vessels (capillaries) in the nail fold. These observations suggest the technique…
Plasma exchange combined with rituximab, an immunosuppressant, might prevent atypical hemolytic uremic syndrome (aHUS) from coming back after a kidney transplant, according to a small study from India. The study, “Kidney Transplant Outcomes in Patients with Atypical Hemolytic Uremic Syndrome,” was published in Transplantation Proceedings. aHUS is…
Recent Posts
- Team care saves mother with trio of postpartum complications
- Once a good side hustle, donating plasma is now too risky for me
- Treatment halts aHUS recurrence after COVID-triggered relapse
- For women like me, hair loss can be particularly devastating
- aHUS drugs restore kidney function in 60% of patients in Romania
- aHUS has changed my life in drastic and unexpected ways
- Rare lupus nephritis–aHUS case improves after Soliris treatment
- How my young children had to adapt to having a sick parent
- Early Soliris use boosts kidney recovery, cuts dialysis need in aHUS
- Dual therapy benefits man with aHUS, Castleman disease